Keyword

BEZ235

Description: An experimental anticancer drug, also called dactolisib, that inhibits phosphoinositide 3-kinase and mammalian target of rapamycin signaling.
Wikidata ID: wiki/Q4835503
OpenAlex ID: keywords/bez235
2013 · Vivian W.Y. Lui, Matthew L. Hedberg, et al. · Cancer Discovery · 662
2018 · Joan B. Mannick, Melody Morris, et al. · Science Translational Medicine · 512
2017 · Afsane Bahrami, Majid Khazaei, et al. · Journal of Cellular Biochemistry · 241
2011 · Nina Ilic, Tamara Utermark, et al. · Proceedings of the National Academy of Sciences · 235
2018 · Tyler Risom, Ellen M. Langer, et al. · Nature Communications · 189
2017 · Safieh Ebrahimi, Mina Hosseini, et al. · Current Medicinal Chemistry · 188
2017 · Heather S. Smallwood, Susu Duan, et al. · Cell Reports · 176
2012 · Patrick J. Roberts, Jerry E. Usary, et al. · Clinical Cancer Research · 157
2013 · Niccolò Bartalucci, Lorenzo Tozzi, et al. · Journal of Cellular and Molecular Medicine · 138
2015 · Andrea Weiss, Xianting Ding, et al. · Angiogenesis · 132
2014 · Neil A. O'Brien, Karen McDonald, et al. · Clinical Cancer Research · 129
2016 · Mª Carmen Herrero-Sánchez, Concepción Rodríguez-Serrano, et al. · Journal of Hematology & Oncology · 124
2010 · H. Burris, J. Rodon, et al. · Journal of Clinical Oncology · 119
Works count: 852
Citation count: 17,080
Year
Topic
Type